Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

An Open-label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

This research study is evaluating an investigational treatment called vedolizumab for moderately to severely active ulcerative colitis (UC) or Crohn's Disease (CD) in children. The purpose of this study is to find out how vedolizumab is processed by the bodies of children with moderately to severely active UC or CD, test to see whether the body makes antibodies against vedolizumab, test how safe vedolizumab is in children, and find out how vedolizumab may affect quality of life and g

QSM for detection of hemorrhaging cysts and risk stratification in ADPKD

This study aims to learn ways to improve the way MRI scans are done to make them more accurate and easier for patients, particularly by using a method that allows them to breathe normally during the scan. 

We also hope to learn ways to improve our understanding of kidney disease. This could lead to better diagnostic tools, more effective treatments, and a deeper insight into kidney function and failure, ultimately benefiting future patients. 

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated).

Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy

The primary objective of this retrospective review is to assess the disease course of implantation mycoses in immunocompromised patients when compared to patients without immunocompromise. The secondary objective is to assess demographic factors associated with patients with this diagnosis within our patient population.

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

Terbinafine is a common oral medication used for moderate to severe nail onychomycosis. On the terbinafine package insert, it states that terbinafine can reduce clearance of caffeine by 19%. However, the clinical effects of this finding in patients have yet to really be studied. The investigators of this study hypothesize that there would be significant changes in blood pressure or heart rate in patients consuming caffeine while taking terbinafine.

Habit Awareness Device for Treatment of Onychophagia

This clinical trial wants to find out if using a special bracelet that vibrates gently whenever someone with a nail-biting problem bites their nails can help them stop. The investigators are looking at adults who bite their nails a lot. If this bracelet works, it could make nail-biters bite their nails less and have a better life.
   
The main question the investigators are trying to answer is: "Does the gentle vibration from the bracelet make people bite their nails less?"
   

A randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve).

 The purpose of this study is to test if an investigational study drug, LMN-201, is safe and effective in treating patients with infection of the lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff). Individuals will be asked to be participants in this research study because they have developed an infection of their lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff).

Real-world evaluation of the HistoSonics Edison® System for treatment of liver tumors across multidisciplinary users

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure.